Literature DB >> 7994940

The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy.

M Akmal1, S Sawelson, F Karubian, M Gadallah.   

Abstract

Hemoccult test was performed on stool specimens of 249 patients; 64 with advanced renal failure prior to dialysis (CRF), 144 on maintenance hemodialysis (HD), and 41 receiving chronic ambulatory peritoneal dialysis CAPD. Each patient collected spontaneously evacuated stool specimens on three different days. None of the patients had overt gastrointestinal bleeding prior to participation in the study. The patients were not taking aspirin, or any other ulcerogenic medication, nor receiving iron supplements at the time of study. Twelve of 64 CRF patients (18.8%), 9 of 144 HD subjects (6.3%), and 3 of 41 CAPD patients (7.3%) had Hemoccult positive stool. Twenty patients underwent diagnostic gastrointestinal (GI) evaluation and these studies demonstrated a definite GI pathology. The commonest lesion was duodenal involvement (alone or in combination with other lesions) and was found in 61.1% of the subjects. The duodenal lesions consisted of superficial erosions, duodenitis, ulcers, polyp, and arteriovenous malformation. The other common lesions were gastritis and hemorrhoids. These results underscore the need for utilization of a simple and non-invasive Hemoccult test in patients with ESRD routinely, and the positive test should be followed by a thorough gastrointestinal work up to identify the cause of occult bleeding.

Entities:  

Mesh:

Year:  1994        PMID: 7994940

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

1.  Wireless capsule endoscopy in the investigation of patients with chronic renal failure and obscure gastrointestinal bleeding (preliminary data).

Authors:  Stephanos Karagiannis; Spyros Goulas; Georgios Kosmadakis; Petros Galanis; Dimitrios Arvanitis; John Boletis; Evangelos Georgiou; Christos Mavrogiannis
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

2.  One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study).

Authors:  Germaine Wong; Richard L Hope; Kirsten Howard; Jeremy R Chapman; Antoni Castells; Simon D Roger; Michael J Bourke; Petra Macaskill; Robin Turner; Gabrielle Williams; Wai Hon Lim; Charmaine E Lok; Fritz Diekmann; Nicholas B Cross; Shaundeep Sen; Richard D M Allen; Steven J Chadban; Carol A Pollock; Allison Tong; Armando Teixeira-Pinto; Jean Y H Yang; Narelle Williams; Eric Hoi Kit Au; Anh Kieu; Laura James; Jonathan C Craig
Journal:  J Am Soc Nephrol       Date:  2019-04-30       Impact factor: 10.121

Review 3.  Gastrointestinal disorders and renal failure: exploring the connection.

Authors:  Shayan Shirazian; Jai Radhakrishnan
Journal:  Nat Rev Nephrol       Date:  2010-07-06       Impact factor: 28.314

4.  Ferumoxytol for treating iron deficiency anemia in CKD.

Authors:  Bruce S Spinowitz; Annamaria T Kausz; Jovanna Baptista; Sylvia D Noble; Renuka Sothinathan; Marializa V Bernardo; Louis Brenner; Brian J G Pereira
Journal:  J Am Soc Nephrol       Date:  2008-06-04       Impact factor: 10.121

5.  Persistent gastric colonization with Burkholderia pseudomallei and dissemination from the gastrointestinal tract following mucosal inoculation of mice.

Authors:  Andrew Goodyear; Helle Bielefeldt-Ohmann; Herbert Schweizer; Steven Dow
Journal:  PLoS One       Date:  2012-05-18       Impact factor: 3.240

6.  Lower gastrointestinal bleeding in chronic hemodialysis patients.

Authors:  Fahad Saeed; Nikhil Agrawal; Eugene Greenberg; Jean L Holley
Journal:  Int J Nephrol       Date:  2011-10-05

7.  Population pharmacokinetic meta-analysis to bridge ferumoxytol plasma pharmacokinetics across populations.

Authors:  Nele Plock; Axel Facius; Gezim Lahu; Nolan Wood; Timothy Frigo; Aaron Deveney; Pau Aceves
Journal:  Clin Pharmacokinet       Date:  2015-04       Impact factor: 6.447

8.  Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.

Authors:  Iain A Gillespie; Iain C Macdougall; Sharon Richards; Vincent Jones; Daniele Marcelli; Marc Froissart; Kai-Uwe Eckardt
Journal:  Pharmacoepidemiol Drug Saf       Date:  2015-02-17       Impact factor: 2.890

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.